Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.79 |
| ▸ | GRK2 | P25098 | 2/20 | 0.65 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | GRK1 | Q15835 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297360 | 0.89 | MMP13 (0.85) | MMP13GRK2 | |
| SCHEMBL6297353 | 0.88 | MMP13 (1.00) | MMP13GRK2GRK5GRK1 | |
| SCHEMBL5697026 | 0.88 | MMP13 (1.00) | MMP13GRK2GRK5GRK1SCD | |
| SCHEMBL5696895 | 0.87 | MMP13 (1.00) | MMP13GRK2GRK5GRK1 | |
| SCHEMBL5696937 | 0.87 | MMP13 (0.78) | MMP13GRK2PDPK1 | |
| SCHEMBL5697007 | 0.86 | MMP13 (1.00) | MMP13GRK2 | |
| SCHEMBL6302790 | 0.86 | MMP13 (0.69) | MMP13GRK2PDPK1 | |
| SCHEMBL5696834 | 0.85 | MMP13 (1.00) | MMP13GRK2GRK5GRK1SCD | |
| SCHEMBL5696952 | 0.85 | MMP13 (1.00) | MMP13GRK2SCD | |
| SCHEMBL6298027 | 0.84 | MMP13 (0.81) | MMP13PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | claimed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6894057-B2 | Oxo-azabicyclic compounds | WARNER-LAMBERT COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6747147-B2 | INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER | WARNER-LAMBERT COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | MMP13 1/4885GRK2 3819/4885GRK5 3509/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | MMP13 1/4885GRK2 235/4885GRK5 858/4885 |
| US-20030220355-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, CA13 | MMP13 1/4885GRK2 3822/4885GRK5 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.